X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The partnership aims to improve the manufacturing of Novo's medicines for serious chronic diseases, including diabetes and obesity medications by leveraging Ginkgo's synthetic biology platform from discovery through new ways of manufacturing.
Lead Product(s): Undisclosed
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Recipient: Ginkgo Bioworks
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration April 10, 2024
Details:
Through the acquisition, Novo Nordisk expand its pipeline in cardiovascular disease by including Cardior’s lead compound CDR132L, currently in phase 2 clinical development for the treatment of heart failure.
Lead Product(s): CDR132L
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CDR132L
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Cardior Pharmaceuticals
Deal Size: $1,110.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition March 25, 2024
Details:
Awiqli (insulin icodec) is a once-weekly basal insulin analogue , which is being evaluated for the treatment of patients with Diabetes Mellitus, Type 2 & Type 1.
Lead Product(s): Insulin Icodec
Therapeutic Area: Endocrinology Product Name: Awiqli
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2024
Details:
Wegovy (Semaglutide) receives FDA approval to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight.
Lead Product(s): Semaglutide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Wegovy
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2024
Details:
NN9487 (amycretin) is a novel oral, unimolecular co-agonist of both GLP-1 and amylin receptors that successfully completed phase 1 trial in Japanese Participants with Obesity
Lead Product(s): Amycretin
Therapeutic Area: Nutrition and Weight Loss Product Name: NN9487
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2024
Details:
Ozempic (semaglutide) belongs to a class of medications known as glucagon-like peptide-1 (GLP-1) receptor agonists. It is being evaluated for the treatment of type 2 diabetes and chronic kidney disease.
Lead Product(s): Semaglutide
Therapeutic Area: Endocrinology Product Name: Ozempic
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2024
Details:
Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management & treatment of obesity.
Lead Product(s): Semaglutide
Therapeutic Area: Nutrition and Weight Loss Product Name: Wegovy
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 29, 2024
Details:
The collaboration leverages Neomorph's leading molecular glue discovery platform and Novo Nordisk's extensive expertise in cardiometabolic and rare diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Undisclosed
Recipient: Neomorph
Deal Size: $1,460.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration February 26, 2024
Details:
Through a license agreement, Almirall gets access of anti-IL-21 monoclonal antibody NN-8828, which it plans to develop for the treatment of immune inflammatory dermatological diseases.
Lead Product(s): NN-8828
Therapeutic Area: Dermatology Product Name: NN-8828
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Almirall
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 19, 2024
Details:
Under the agreement, Novo Nordisk has obtained all exclusive rights to develop and commercialize EraCal’s oral small molecule asset to control appetite and body weight with an eye toward treating obesity.
Lead Product(s): Undisclosed
Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Recipient: Eracal Therapeutics
Deal Size: $255.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 23, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
